Search results

Found 150 pages
AUTHOR: PharmaTimes Reporter

Results per page

10 20 50 100

Sort by

Relevance Date

7 Jun 2013:

Abilify on track for NHS funding approval

NICE has issued draft guidance recommending Lundbeck/Otsuka’s Abilify for the treatment of teenagers with bipolar disorder - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/abilify_on_track_for_nhs_funding_approval_1005157

29 Aug 2013:

FDA finalises guidance on IRB responsibilities

The US Food and Drug Administration (FDA) has published a new document consolidating its guidance for institutional review boards (IRBs) as they review the adequacy of biomedical research sites and clinical investigators. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/fda_finalises_guidance_on_irb_responsibilities_1005606

12 Jun 2013:

ABPI demands more data from NHS

The ABPI is calling for the NHS to give it more data on the uptake and access to new medicines. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/abpi_demands_more_data_from_nhs_1005182

21 Aug 2013:

MSD needs to cut costs, says analyst

MSD needs to undertake a "major restructuring" in the wake of lacklustre sales and recent R&D setbacks, according to analysts at Leerink Swann. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/msd_needs_to_cut_costs,_says_analyst_1005573

28 May 2013:

Pharma pays $1bn for US doctor influence

Pharma spending on US doctors topped $1 billion last year as the industry braces for the arrival of the Sunshine Act. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/pharma_pays_$1bn_for_us_doctor_influence_1005093

27 Aug 2013:

Amgen agrees $10.4bn deal for Onyx

Amgen has thrashed out an all-cash deal to buy cancer specialist Onyx for $10.4 billion which should close in the fourth quarter. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/amgen_agrees_$10.4bn_deal_for_onyx_1005592

29 Aug 2013:

Global CROs see sales leap ahead in 2012

Revenues reported by contract research organisations (CROs) rose more than 10% last year to reach $13.6 billion, driven by greater demand for outsourced clinical services - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/global_cros_see_sales_leap_ahead_in_2012_1005607

13 Aug 2013:

Vical tanks after dropping melanoma therapy

Shares in US biotech Vical fell through the floor yesterday after it announced the demise of its Allovectin immunotherapy for advanced melanoma. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/vical_tanks_after_dropping_melanoma_therapy_1005539

28 Aug 2013:

Akorn buys Hi-Tech Pharmacal for $640m

Generic drugmaker Akorn has agreed a $640 million cash deal to acquire Hi-Tech Pharmacal to diversify its pipeline beyond ophthalmic pharmaceuticals. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/akorn_buys_hi-tech_pharmacal_for_$640m_1005599

18 Dec 2013:

Pfizer settles with Teva over generic Viagra

Pfizer has settled a long-running legal dispute with Teva with a deal that will allow the Israeli company to launch a generic version of erectile dysfunction (ED) drug Viagra in the US in 2017. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/pfizer_settles_with_teva_over_generic_viagra_1006205